A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma
Brain and Nervous System
What is the purpose of this trial?
The main purpose of this study is to compare how long patients with glioblastoma (GBM, a malignant brain cancer) live after receiving nivolumab every two weeks in addition to radiation therapy (RT), and then every four weeks, compared with patients receiving standard therapy with temozolomide in addition to RT.
- Trial withBristol-Myers Squibb Research and Development
- Start Date09/11/2016
- End Date02/28/2019
- Last Updated06/22/2018
- Study HIC#1604017516